VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure
In connection with the attendance of VIVUS,Inc. (the “Company”) at meetings and presentations at the 37thAnnual J.P. Morgan Healthcare Conference to be held in San Francisco, California on January7, 2019 through January10, 2019, the Company will be distributing and presenting the slides attached hereto as Exhibit99.1; such slides are incorporated by reference herein.
The information furnished under this Item 7.01, including the related exhibit, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
VIVUS INC Exhibit
EX-99.1 2 a19-1323_1ex99d1.htm EX-99.1 Exhibit 99.1 January 2019 Reinvigorate,…
To view the full exhibit click here
About VIVUS,INC. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
